188 related articles for article (PubMed ID: 36323699)
1. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
[TBL] [Abstract][Full Text] [Related]
2. Liver X receptor α induces 17β-hydroxysteroid dehydrogenase-13 expression through SREBP-1c.
Su W; Peng J; Li S; Dai YB; Wang CJ; Xu H; Gao M; Ruan XZ; Gustafsson JÅ; Guan YF; Zhang XY
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E357-E367. PubMed ID: 28270440
[TBL] [Abstract][Full Text] [Related]
3. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
4. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.
Su W; Wang Y; Jia X; Wu W; Li L; Tian X; Li S; Wang C; Xu H; Cao J; Han Q; Xu S; Chen Y; Zhong Y; Zhang X; Liu P; Gustafsson JÅ; Guan Y
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11437-42. PubMed ID: 25028495
[TBL] [Abstract][Full Text] [Related]
5. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease.
Wang MX; Peng ZG
Pharmacol Ther; 2023 Jun; 246():108428. PubMed ID: 37116587
[TBL] [Abstract][Full Text] [Related]
6. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
Pirola CJ; Garaycoechea M; Flichman D; Arrese M; San Martino J; Gazzi C; Castaño GO; Sookoian S
J Lipid Res; 2019 Jan; 60(1):176-185. PubMed ID: 30323112
[TBL] [Abstract][Full Text] [Related]
7. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
8. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of
Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
[TBL] [Abstract][Full Text] [Related]
10. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
[TBL] [Abstract][Full Text] [Related]
11. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
12. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.
Luukkonen PK; Tukiainen T; Juuti A; Sammalkorpi H; Haridas PAN; Niemelä O; Arola J; Orho-Melander M; Hakkarainen A; Kovanen PT; Dwivedi O; Groop L; Hodson L; Gastaldelli A; Hyötyläinen T; Orešič M; Yki-Järvinen H
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161197
[TBL] [Abstract][Full Text] [Related]
13. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
14. Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.
Zhang X; Wang Y; Liu P
Protein Cell; 2017 Jan; 8(1):4-13. PubMed ID: 27757845
[TBL] [Abstract][Full Text] [Related]
15. Role of HSD17B13 in the liver physiology and pathophysiology.
Su W; Mao Z; Liu Y; Zhang X; Zhang W; Gustafsson JA; Guan Y
Mol Cell Endocrinol; 2019 Jun; 489():119-125. PubMed ID: 30365983
[TBL] [Abstract][Full Text] [Related]
16. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.
Abul-Husn NS; Cheng X; Li AH; Xin Y; Schurmann C; Stevis P; Liu Y; Kozlitina J; Stender S; Wood GC; Stepanchick AN; Still MD; McCarthy S; O'Dushlaine C; Packer JS; Balasubramanian S; Gosalia N; Esopi D; Kim SY; Mukherjee S; Lopez AE; Fuller ED; Penn J; Chu X; Luo JZ; Mirshahi UL; Carey DJ; Still CD; Feldman MD; Small A; Damrauer SM; Rader DJ; Zambrowicz B; Olson W; Murphy AJ; Borecki IB; Shuldiner AR; Reid JG; Overton JD; Yancopoulos GD; Hobbs HH; Cohen JC; Gottesman O; Teslovich TM; Baras A; Mirshahi T; Gromada J; Dewey FE
N Engl J Med; 2018 Mar; 378(12):1096-1106. PubMed ID: 29562163
[TBL] [Abstract][Full Text] [Related]
17. Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
Wang M; Li J; Li H; Dong B; Jiang J; Liu N; Tan J; Wang X; Lei L; Li H; Sun H; Tang M; Wang H; Yan H; Li Y; Jiang J; Peng Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628360
[TBL] [Abstract][Full Text] [Related]
18. 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
Ma Y; Brown PM; Lin DD; Ma J; Feng D; Belyaeva OV; Podszun MC; Roszik J; Allen JN; Umarova R; Kleiner DE; Kedishvili NY; Gavrilova O; Gao B; Rotman Y
Hepatology; 2021 May; 73(5):1701-1716. PubMed ID: 32779242
[TBL] [Abstract][Full Text] [Related]
19. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
[TBL] [Abstract][Full Text] [Related]
20. N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice.
Bhagat HA; Compton SA; Musso DL; Laudeman CP; Jackson KMP; Yi NY; Nierobisz LS; Forsberg L; Brenman JE; Sexton JZ
PLoS One; 2018; 13(10):e0204605. PubMed ID: 30359371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
